dc.contributor.author | Kvinge, Alexander Dåtland | |
dc.contributor.author | Kvammen, Tobias | |
dc.contributor.author | Miletic, Hrvoje | |
dc.contributor.author | Bindoff, Laurence Albert | |
dc.contributor.author | Reikvam, Håkon | |
dc.date.accessioned | 2022-12-19T13:42:38Z | |
dc.date.available | 2022-12-19T13:42:38Z | |
dc.date.created | 2022-12-05T09:17:49Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 1198-0052 | |
dc.identifier.uri | https://hdl.handle.net/11250/3038596 | |
dc.description.abstract | Musculoskeletal graft versus host disease (GVHD) is a rare manifestation of chronic GVHD (cGVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Left untreated, the disease can cause extensive damage to muscle tissue and joints. We describe a 62-year-old male with musculoskeletal GVHD and generalized muscle pain and stiffness. In addition, we performed a systemic literature review based on published cases of musculoskeletal GVHD between 1983 and 2019. We identified 85 cases, 62% male and 38% female with an age of 4–69 years and median age of 39 years at diagnosis. The majority of patients (72%) also had manifestations of cGVHD in at least one other organ system, most frequently the skin (52%), followed by oropharyngeal mucosa (37%), and pulmonary and gastrointestinal tract (GI tract) (21%). We conclude that, while musculoskeletal cGVHD is a rare complication of allo-HSCT, it remains a serious and debilitating risk that must be considered in patients with muscle pain, muscle weakness, joint stiffness, and tissue inflammation. Early intervention is critical for the patient’s prognosis. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Musculoskeletal Chronic Graft versus Host Disease-A Rare Complication to Allogeneic Hematopoietic Stem Cell Transplant: A Case-Based Report and Review of the Literature | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 The Author(s) | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.3390/curroncol29110663 | |
dc.identifier.cristin | 2088441 | |
dc.source.journal | Current Oncology | en_US |
dc.source.pagenumber | 8415-8430 | en_US |
dc.identifier.citation | Current Oncology. 2022, 29 (11), 8415-8430. | en_US |
dc.source.volume | 29 | en_US |
dc.source.issue | 11 | en_US |